UCL has made dementia a priority
Dementia is the greatest scientific, medical and socio-economic challenge of our times and affects more than 46 million people worldwide. As populations age, dementia is inevitably going to become more common with devastating personal, social and economic implications.
UCL can lay claim to world-leading expertise across the spectrum of research, from genetics to evidence based treatments and support for patients and carers. We have both the ambition and ability to make a difference and meet the challenge of this most pressing of global public health problems.
The UK Dementia Research Institute is a joint investment into dementia research led by the Medical Research Council alongside founding charity partners Alzheimer’s Society and Alzheimer’s Research UK. The Institute will be catalytic in the UK’s research efforts to diagnose, treat, care for and prevent dementias, a group of neurodegenerative disorders which include Alzheimer’s, Parkinson’s, Huntington’s disease and vascular dementia. The hub of the institute activity and operational headquarters is based at UCL.
The UK Dementia Research Institute (UK DRI), which is headquartered at UCL, will receive £40m of UK Government funding via the Medical Research Council, helping ensure its pioneering research is conducted in first-class facilities.
Published: Mar 12, 2018 12:35:50 PM
The 2018 Brain Prize, the world’s most valuable prize for brain research at €1m, has been awarded to Professor John Hardy (UCL Institute of Neurology) and Professor Bart De Strooper (UK Dementia Research Institute at UCL) for their groundbreaking research on the genetic and molecular basis of Alzheimer’s disease.
Published: Mar 6, 2018 3:00:10 PM